Skip to main content
Log in

Metabolic bone disease in patients with liver disease

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

The coexistence of liver disease and osteopenic bone disease has been recognized for many years and is now the subject of increasing attention. Osteoporosis has been characterized well in patients with cholestatic liver disease, but new research suggests that osteopenia and osteoporosis may also be prevalent in patients with other chronic liver diseases. Although the precise mechanism of bone loss remains unclear, advances in treatment and prevention are bringing heightened awareness to this common problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hughes DE, Dai A, Tiffee JC, et al.: Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996, 2:1132–1136.

    Article  PubMed  CAS  Google Scholar 

  2. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al.: Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998, 28:695–699.

    Article  PubMed  CAS  Google Scholar 

  3. Hattori N, Kurahachi H, Ikekubo K, et al.: Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis. Metab Clin Exper 1992, 41:377–381.

    CAS  Google Scholar 

  4. Janes CH, Dickson ER, Okazaki R, et al.: Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995, 95:2581–2586.

    Article  PubMed  CAS  Google Scholar 

  5. Guanabens N, Pares A, Marinoso L, et al.: Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990, 85:1356–1362.

    PubMed  CAS  Google Scholar 

  6. Hodgson S, Dickson E, Wahner H, et al.: Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985, 103:855–860.

    PubMed  CAS  Google Scholar 

  7. Duarte MP, Farias ML, Coelho HS, et al.: Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001, 16:1022–1027.

    Article  PubMed  CAS  Google Scholar 

  8. Lindor KD, Jorgensen RA, Tiegs RD, et al.: Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000, 33:878–882.

    Article  PubMed  CAS  Google Scholar 

  9. Guanabens N, Pares A, Alvarez L, et al.: Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998, 13:731–738.

    Article  PubMed  CAS  Google Scholar 

  10. Hay JE, Lindor KD, Wiesner RH, et al.: The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991, 14:257–261.

    PubMed  CAS  Google Scholar 

  11. Matloff D, Kaplan M, Neer R, et al.: Osteoporsis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenteroogy 1981, 83:97–102.

    Google Scholar 

  12. Herlong H, Becker R, Maddrey W: Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982, 83:103–108.

    PubMed  CAS  Google Scholar 

  13. Gong G, Stern H, Cheng S, et al.: The association of bone mineral density with vitamin d receptor gene polymorphisms. Osteoporos Int 1999, 9:55–64.

    Article  PubMed  CAS  Google Scholar 

  14. Pares A, Guanabens N, Alvarez L, et al.: Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001, 33:554–560. This Spanish study of 61 women with primary biliary cirrhosis found no relationship between vitamin D receptor genotypes and bone mass.

    Article  PubMed  CAS  Google Scholar 

  15. Springer JE, Cole DE, Rubin LA, et al.: Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000, 118:145–51.

    Article  PubMed  CAS  Google Scholar 

  16. Guardiola J, Xiol X, Sallie R, et al.: Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation. Ann Intern Med 1999, 131:752–755.

    PubMed  CAS  Google Scholar 

  17. Hay JE: Vitamin D receptor polymorphism and posttransplantation bone loss. Liver Transpl 2001, 7:68–69.

    Article  PubMed  CAS  Google Scholar 

  18. Bell H, Raknerud N, Falch J, Haug E: Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis. Eur J Endocrinol 1995, 132:444–449.

    PubMed  CAS  Google Scholar 

  19. Turner R: Skeletal response to alcohol. Alcohol Clin Exp Res 2000, 24:1693–1701.

    Article  PubMed  CAS  Google Scholar 

  20. Mitchison H, Malcolm A, Bassendine M, James O: Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988, 94:463–470.

    PubMed  CAS  Google Scholar 

  21. Porayko MK, Wiesner RH, Hay JE, et al.: Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc 1991, 23:1462–1465.

    PubMed  CAS  Google Scholar 

  22. Eastell R, Dickson ER, Hodgson SF, et al.: Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991, 14:296–300.

    Article  PubMed  CAS  Google Scholar 

  23. Camisasca M, Crosignani A, Battezzati P: Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994, 20:633–637.

    Article  PubMed  CAS  Google Scholar 

  24. Ormarsdottir S, Ljunggren O, Mallmin H, et al.: Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol 1999, 31:84–90.

    Article  PubMed  CAS  Google Scholar 

  25. Angulo P, Therneau TM, Jorgensen A, et al.: Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998, 29:729–735.

    Article  PubMed  CAS  Google Scholar 

  26. Corazza G, Trevisani F, Di Stefano M, et al.: Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig Dis Sci 2000, 45:1392–1399. This Italian study confirmed that patients with viral cirrhosis have an increased rate of bone resorption when compared with healthy volunteers.

    Article  PubMed  CAS  Google Scholar 

  27. Chen C, Wang S, Jeng F, Lee S: Metabolic bone disease of liver cirrhosis: is it a parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996, 11:417–421.

    PubMed  CAS  Google Scholar 

  28. Solis-Herruzo J, Castellano G, Fernandez I, et al.: Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000, 33:812–817.

    Article  PubMed  CAS  Google Scholar 

  29. Trautwein C, Possienke M, Schlitt H, et al.: Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000, 95:2343–2351.

    Article  PubMed  CAS  Google Scholar 

  30. Carey EJ, Balan V, Kremers WK, Hay JE: Osteopenia and fracturing in hepatitis C and alcoholic liver disease: not just a cholestatic problem [abstract]. Gastroenterology 2002, 122:A531.

    Article  CAS  Google Scholar 

  31. Peris P, Guanabens N, Pares A, et al.: Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 1995, 57:111–114.

    Article  PubMed  CAS  Google Scholar 

  32. Peris P, Pares A, Guanabens N, et al.: Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol Alcohol 1992, 27:619–625.

    PubMed  CAS  Google Scholar 

  33. Rubin E, Caballeria J, Rodes J, Munoz J: Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 1995, 57:111–114.

    Article  Google Scholar 

  34. Bikle DD, Stesin A, Halloran B, et al.: Alcohol-induced bone disease: relationship to age and parathyroid hormone levels. Alcohol Clin Exp Res 1993, 17:690–695.

    Article  PubMed  CAS  Google Scholar 

  35. Schnitzler CM, Solomon L: Bone changes after alcohol abuse. South Afr Med J 1984, 66:730–734.

    CAS  Google Scholar 

  36. Siris E, Miller P, Barrett-Connor E, et al.: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA 2001, 286:2815–2822.

    Article  PubMed  CAS  Google Scholar 

  37. Felson D, Zhang Y, Hannan M, et al.: Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995, 142:485–492.

    PubMed  CAS  Google Scholar 

  38. Santolaria F, Gonzalez-Reimers E, et al.: Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. Alcohol 2000, 22:147–157.

    Article  PubMed  CAS  Google Scholar 

  39. Epstein O, Kato Y, Dick R, Sherlock S: Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982, 36:426–430.

    PubMed  CAS  Google Scholar 

  40. Matloff DS, Kaplan MM, Neer RM, et al.: Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982, 83:97–102.

    PubMed  CAS  Google Scholar 

  41. Crippin J, Jorgensen R, Dickson E, Lindor K: Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994, 89:47–50.

    PubMed  CAS  Google Scholar 

  42. Collier JD, Ninkovic M, Compston JE: Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002, 50:1–9. A brief review of the literature with consensus guidelines on current management of osteoporosis in chronic liver disease.

    Article  Google Scholar 

  43. Shiomi S, Masaki K, Habu D, et al.: Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 1999, 14:547–552.

    Article  PubMed  CAS  Google Scholar 

  44. Olsson R, Mattsson L, Obrant K, Mellstrom D: Estrogenprogestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999, 19:188–192.

    Article  PubMed  CAS  Google Scholar 

  45. Floreani A, Zappala F, Fries W, et al.: A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997, 24:239–244.

    Article  PubMed  CAS  Google Scholar 

  46. Hay J, Malinchoc M, Dickson R: A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2001, 34:292–298. This randomized, controlled trial of 63 patients undergoing liver transplantation for cholestatic liver disease established the lack of benefit of calcitonin on bone density or fracture.

    Article  PubMed  Google Scholar 

  47. Wolfhagen F, van Buuren H, den Ouden J, et al.: Cyclical etidronate in the prevention of bone los in corticosteroidtreated primary biliary cirrhosis: a prospective, controlled pilot study. J Hepatol 1997, 26:325–330.

    Article  PubMed  CAS  Google Scholar 

  48. Guanabens N, Farrerons J, Perez-Edo L, et al.: Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. Bone 2000, 27:123–128.

    Article  PubMed  CAS  Google Scholar 

  49. Pares A, Guanabens N, Ros I, et al.: Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis [abstract]. Hepatology 1999, 30:472A.

    Article  Google Scholar 

  50. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.

    Article  PubMed  CAS  Google Scholar 

  51. Guanabens N, Pares A, del Rio L, et al.: Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992, 15:345–349.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carey, E., Balan, V. Metabolic bone disease in patients with liver disease. Curr Gastroenterol Rep 5, 71–77 (2003). https://doi.org/10.1007/s11894-003-0012-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-003-0012-z

Keywords

Navigation